The Role Of Cyp2d6, Cyp3a4/5, And Abcb1 Polymorphisms In Patients Using Long-Acting Injectable Risperidone (CROSBI ID 650071)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Ganoci, Lana ; Lovrić, Mila ; Živković, Maja ; Šagud, Marina ; Klarica Domjanović, Iva ; Božina, Nada
engleski
The Role Of Cyp2d6, Cyp3a4/5, And Abcb1 Polymorphisms In Patients Using Long-Acting Injectable Risperidone
A study of the serum concentration of the active substance of long-acting risperidone was compared to CYP2D6, CYP3A5 and ABCB1 genotypes. Slow metabolizers of CYP2D6 had elevated and ultra fast metabolizers of CYP2D6 reduced concentrations of the active substance. Other genotypes had no effect on the concentration of risperidone + 9-OH risperidone.
CYP2D6 genotypes, CYP3A4/5 genotypes, P-glycoprotein, Long-acting risperidone
DOI: 10.1016/j.clinthera.2016.07.110 ; https://doi.org/10.1016/j.clinthera.2016.07.110
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
e10-e11.
2016.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
Clinical therapeutics
0149-2918
Podaci o skupu
European Association for Clinical Pharmacology and Therapeutics (EACPT) Focus Meeting 2016 : How to Assess Medicines from Research to Clinical Practice? Efficacy, Effectiveness, and Economic – 3E Assessment ; European Association for Clinical Pharmacology and Therapeutics (EACPT) Focus Meeting 2016 : How to Assess Medicines from Research to Clinical Practice? Efficacy, Effectiveness, and Economic
poster
06.10.2016-09.10.2016
Opatija, Hrvatska
Povezanost rada
Kliničke medicinske znanosti
